Recurrences and Deaths Prevented by Atezolizumab Translate to Lower Cost of Care
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
JADPRO 2022
Undetectable PSA Levels Tied to Improvements in rPFS, OS in Metastatic Hormone-Sensitive Prostate Cancer
Patients with mHSPC who receive enzalutamide plus ADT are 4 times more likely to achieve undetectable PSA levels than patients who receive ADT alone, according to an analysis of data from the ARCHES trial.
Risk of VTE 6-Fold Higher in CLL/MBL Than in General Population
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
More Resources Needed for African-American Women Who Survive Breast Cancer
African-American women who survive breast cancer do not get adequate resources to support their mental and emotional health, a small study suggests.
Palbociclib Improves Outcomes of HR+/HER2- Metastatic Breast Cancer in Real World
Real-world data support first-line palbociclib plus an aromatase inhibitor as standard care for HR+, HER2- metastatic breast cancer, according to researchers.
Cost and Coordination of Care Head List of Concerns With Combination IV/Oral Therapy
Results of an ACCC study revealed advanced practitioners’ greatest challenges when treating cancer patients with combination IV/oral therapies.
Still Unclear Whether Intermittent Fasting Can Improve Cancer Outcomes
Intermittent fasting appears safe as an adjunct to chemotherapy, but it is unclear whether this diet can improve cancer outcomes.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in JADPRO 2022
Loading... 
Loading...